Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

@article{Jeppesen1996DosedependentIO,
  title={Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine},
  author={U. Jeppesen and L. F. Gram and K. Vistisen and S. Loft and H. Poulsen and K. Br{\o}sen},
  journal={European Journal of Clinical Pharmacology},
  year={1996},
  volume={51},
  pages={73-78}
}
  • U. Jeppesen, L. F. Gram, +3 authors K. Brøsen
  • Published 1996
  • Medicine
  • European Journal of Clinical Pharmacology
  • Objectives: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine and paroxetine. [...] Key Method The volunteers received in randomised order, at weekly intervals, increasing single oral doses of one of the four SSRIs, followed 3 h later by sparteine (CYP2D6), mephenytoin (CYP2C19) and caffeine (CYP1A2) tests. Fluoxetine…Expand Abstract

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 47 REFERENCES
    Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.
    • 144
    A fluvoxamine-caffeine interaction study.
    • 98